Details

Autor(en) / Beteiligte

• Fischer, Luise
• Grieb, Nora
• Born, Patrick
• Weiss, Ronald
• Seiffert, Sabine
• Boldt, Andreas
• Fricke, Stephan
• Franz, Paul
• Heyn, Simone
• Kubasch, Anne Sophie
• Baber, Ronny
• Weidner, Heike
• Wang, Song Yau
• Bach, Enrica
• Hoffmann, Sandra
• Ussmann, Jule
• Kirchberg, Janine
• Hell, Saskia
• Schwind, Sebastian
• Metzeler, Klaus H
• Herling, Marco
• Jentzsch, Madlen
• Franke, Georg-Nikolaus
• Sack, Ulrich
• Reiche, Kristin
• Köhl, Ulrike
• Platzbecker, Uwe
• Vucinic, Vladan
• Merz, Maximilian

Titel

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Ist Teil von

• Leukemia, 2024-02, Vol.38 (2), p.372-382

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2024

Quelle

Nexis

Beschreibungen/Notizen

• B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8 CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8 T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented.